Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Freeline Therapeutics Stock (NASDAQ:FRLN) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Freeline Therapeutics alerts:Sign Up Key Stats Today's Range$6.48▼$6.4850-Day Range$6.43▼$6.4952-Week Range$2.11▼$8.74VolumeN/AAverage Volume12,055 shsMarket Capitalization$28.12 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingHold Company OverviewFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Read More… Elon Musk has put himself in their crosshairs (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FRLN Stock News HeadlinesFreeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingApril 24, 2024 | globenewswire.comFreeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.November 14, 2024 | Porter & Company (Ad)Acquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | finance.yahoo.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | globenewswire.comFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 13, 2024 | finanznachrichten.deFreeline Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comFreeline Therapeutics Holdings plc (FRLN)February 9, 2024 | uk.finance.yahoo.comSee More Headlines FRLN Stock Analysis - Frequently Asked Questions How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($15.20) by $2.30. When did Freeline Therapeutics' stock split? Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Freeline Therapeutics IPO? Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/09/2021Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:FRLN CUSIPN/A CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$6.50 Low Stock Price Target$6.50 Potential Upside/Downside+0.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.5939) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-150.46% Return on Assets-97.01% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.54Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$28.12 million OptionableNot Optionable Beta0.66 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:FRLN) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Freeline Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.